Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$431.27MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William J. Sibold
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 915
- Beta
- -1.00
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 5.90
Financials
Revenue
$431.27M+2846.2%Net Income
$55.44MEBITDA
$63.90MFree Cash Flow
$116.63MEPS (diluted)
$1.83Shares Outstanding (diluted)
30.31M+163.4%Operating Expenses
$337.46MCash & Debt
$960.97MRevenue by Segment (annual)
$958.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $958.40M | $-288.28M | $-12.85 |
| 2024 | $180.13M | $-465.89M | $-21.90 |
| 2023 | $0.00 | $-373.63M | $-19.99 |
| 2022 | $0.00 | $-295.35M | $-17.23 |
| 2021 | $0.00 | $-241.85M | $-14.63 |
| 2020 | $0.00 | $-202.24M | $-13.09 |
| 2019 | $0.00 | $-83.95M | $-4.73 |
| 2018 | $0.00 | $-32.81M | $-2.22 |
| 2017 | $0.00 | $-31.15M | $-2.54 |
| 2016 | $0.00 | $-26.39M | $-5.07 |
| 2015 | $0.00 | $-6.84M | $-401.56 |
| 2014 | $0.00 | $-86.16M | $-30.62 |
| 2013 | $0.00 | $-90.19M | $-44.48 |
| 2012 | $0.00 | $-62.79M | $-36.99 |
Valuation
MDGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
27-76.47%Social Signal Score
Mentions (27)
- Newsnewsfilecorp.com·3d ago·Negative
Kaplan Fox Reminds Madrigal Pharmaceuticals, Inc. (MDGL) Investors of an Investigation into Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that cou…
View source ↗ - Newsglobenewswire.com·4d ago·Negative
Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in…
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsnewsfilecorp.com·5d ago·Negative
Kaplan Fox Notifies Madrigal Pharmaceuticals, Inc. (MDGL) Investors of a Securities Investigation into the Company New York, New York--(Newsfile Corp. - November 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in …
View source ↗ - Newsglobenewswire.com·9d ago·Negative
Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that co…
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
View source ↗ - Newsnewsfilecorp.com·12d ago·Negative
Kaplan Fox Alerts Madrigal Pharmaceuticals, Inc. (MDGL) Investors to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could …
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that cou…
View source ↗ - Newsbusinesswire.com·13d ago·Negative
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MDGL--MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…nts in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place Nov. 5–9 in Denv…
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy Madrigal Pharmaceuticals delivered another earnings beat, with Q3 net sales up 50% YoY, and Rezdiffra's blockbuster status confirmed. Despite exceeding expectations, MDGL shares fell ~8% post-earnings, potentially due to a whistleblower disclosure. Rezdiffra has only ~10% market penetration in a rapidly expanding MASH market, with significant growth potential and patent protection into 2045.
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Madrigal anticipates late 2027 MAESTRO-NASH OUTCOMES readout while planning 2,000+ patient MAESTRO-CSPH study
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)investing·19d ago·Neutral
Why is Madrigal Pharmaceuticals stock surging today?
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call Madrigal Pharmaceuticals NASDAQ: MDGL reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to add patients and expand its prescriber base. Year-to-date net sales reached $1.1 billion, and the company reported its first profitable quarter.
View source ↗ - Newszacks.com·19d ago·Neutral
Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates Madrigal (MDGL) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of a loss of $1.09 per share. This compares to a loss of $5.08 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.
View source ↗ - Newszacks.com·26d ago·Neutral
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
…ment response, cardiovascular risk markers and patient-reported outcomes CONSHOHOCKEN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Dise…
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·73d ago·Neutral
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·99d ago·Neutral
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Madrigal Appoints John C. Reed, M.D. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $1.43 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$1.83 vs $-0.86beat
- Thu, Jul 30$-1.99 vs $-2.68beat
- Wed, May 6$-3.25 vs $-3.61beat
- Thu, Feb 19$-2.57 vs $0.04miss
- Tue, Nov 4$-5.08 vs $-2.04miss
- Tue, Aug 5$-1.90 vs $-3.48beat
Estimates and results for MDGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDGL officers and directors.
- Bought
- $35.0m
- Sold
- $14.9m
5 trades
67 trades
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Kelley Shannon Tsold
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Sibold William Johnsold
- Sibold William Johnsold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
